Acquisition Of Prometheus Biosciences Inc. ( RXDX)
BY Reuters
— 6:07 AM ET 04/16/2023
April 16 (Reuters) - Merck & Co Inc (MRK):
* MERCK STRENGTHENS IMMUNOLOGY PIPELINE WITH ACQUISITION OF PROMETHEUS BIOSCIENCES, INC.
* MERCK (MRK)- MERCK (MRK), THROUGH A SUBSIDIARY, HAS AGREED TO ACQUIRE PROMETHEUS FOR $200.00 PER SHARE IN CASH FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $10.8 BILLION.
* MERCK (MRK)- TRANSACTION IS EXPECTED TO CLOSE IN Q3 OF 2023.
* MERCK (MRK)- MERCK (MRK), THROUGH A SUBSIDIARY, WILL ACQUIRE ALL OF OUTSTANDING SHARES OF PROMETHEUS Source text for Eikon: Further company coverage:
--------------------------
Kiwi
